BioCentury on BioBusiness,
Product Discovery & Development
Cholesterol data from Amgen sheds light on race between anti-PCSK9 mAbs
Related tables, figures and sidebars
Piecing together PCSK9
Monday, November 12, 2012
Last week's Phase II data for anti-PCSK9 mAbs from Amgen
Inc. and Pfizer
Inc. revealed no surprises and kept intact the hypothesis that hitting
the target is a new modality for lowering cholesterol with or without statin
background therapy. The data do allow for a rough comparison between Amgen's
molecule and the most advanced member of the class - twice monthly REGN727 from
Pharmaceuticals Inc. and Sanofi
- and show no clear winner.
While Pfizer is keeping mum on
how it hopes to differentiate its RN316 (PF-04950615) from the pack, Amgen
thinks it could come down to dosing. Indeed, the biotech bellwether hopes to
counter REGN727's six to nine month head start in the clinic by offering a
monthly dosing option for AMG 145.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]